Antibiotics Market Trends

Report ID: GMI8014
Published Date: Feb 2024
Report Format: PDF

Download Free Sample

Antibiotics Market Trends

Growing awareness of antibiotic-resistance has led the pharmaceutical and biopharmaceutical companies to increasingly focus on developing combination drugs for additive and synergistic effects. For instance, in March 2022, Venatorx Pharmaceutical reported positive clinical phase III data for cefepime-taniborbactam, a combination antibiotic therapy for severe UTIs. This research initiative aimed to investigate potential for the application expansion of combination antibiotics.
Similarly, in May 2023, Entasis Therapeutics received the U.S Food and Drug Administration (FDA) approval for Xacduro, a combination antibiotic of sulbactam and durlobactam for hospital-related bacterial pneumonia therapeutics caused by a highly resistant superbug. This approval aimed to introduce the antibiotic combination to broaden the scope of treatment options for hospital-acquired pneumonia.
Furthermore, increased awareness in public health, focusing on generic drug development, and government initiatives against antibiotic resistance contributed to the increase product demand, thereby driving the market progress.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global antibiotics industry was valued at USD 45.6 billion in 2023 and is expected to reach USD 60.9 billion by 2032 growing at a CAGR of 3.3% over the analysis period driven by the growing aging population and the continual development of novel antibiotic formulations.

The UTI application is expected to lead the market, projecting the revenue of USD 23.3 billion by 2032, owing to the high incidence of UTIs, particularly among women, that propels the need for antibiotics such as ciprofloxacin and trimethoprim-sulfamethoxazole, crucial in managing these infections.

North America antibiotics market is expected to record strong CAGR throughout 2024 and 2032 due to the high incidence of infectious diseases such as pneumonia and TB.

Abbott Laboratories, AbbVie, Inc., Allergan plc, Basilea Pharmaceutica Ltd., Bayer AG, Bristol Myers Squibb, Cipla Inc., Daiichi Sankyo Company Ltd., Eli Lilly & Co., GlaxoSmithKline plc., Johnson & Johnson, Lupin Inc., Melinta Therapeutics LLC, Merck & Co., Novartis AG, Pfizer Inc., Sandoz, Sanofi, Teva Pharmaceutical Industries Ltd., and Viatris Inc.